Llombart-Cussac, A., García, J. M. P., López-Miranda, E., Saavedra, C., Carañana, V., Blancas, I., González, C. H., Cortes-Salgado, A., Calvo, E. G., Xiang, R. R. Z., Alcalá-López, D., Santos, J. C., Boix, O., Garrido, A., Barrios, C. H., Curigliano, G., Bartsch, R., Hardy-Bessard, A., Wasserman, T., Cortés, J. (2026). ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2− advanced breast cancer (aBC) patients with
                    <i>ESR1</i>
                    -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1154